Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099564 | 1.00 | ALK (0.41) | ALKTACR1RENKCNH2TSHR | |
| SCHEMBL556576 | 0.89 | TACR1 (0.37) | TACR1RENKCNH2TSHRALOX15 | |
| SCHEMBL2404325 | 0.89 | ALK (0.43) | ALKTACR1TSHRALOX15GPR119 | |
| SCHEMBL555641 | 0.89 | TACR1 (0.37) | ALKTACR1RENKCNH2TSHR | |
| SCHEMBL556775 | 0.87 | TACR1 (0.36) | ALKTACR1RENKCNH2TSHR | |
| SCHEMBL556532 | 0.78 | REN (0.37) | RENKCNH2CYP3A4 | |
| SCHEMBL8194747 | 0.78 | ALK (0.49) | ALKGPR119 | |
| SCHEMBL8194742 | 0.78 | ALK (0.49) | ALKGPR119 | |
| SCHEMBL8194760 | 0.77 | YAP1 (0.49) | ALKTACR1GPR119 | |
| SCHEMBL8194978 | 0.77 | YAP1 (0.49) | ALKTACR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | NOVARTIS AG | 2010-10-07 | — | — | US | disclosed |
| EP-2212315-A1 | TRISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050253-A1 | TRISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | REN, AGTR1, AGTR2 | ALK 1756/4885TACR1 44/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.